FimmCyte
PrivateLast Round
Convertible Debt
Feb 29, 2024
Total Funding Raised
$2.69M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
FimmCyte operates in Healthcare & Life Sciences and is based in Basel. Its latest recorded funding round was a Convertible Debt round in February 2024.
FimmCyte is a biotechnology company developing targeted immunotherapies for chronic fibro-inflammatory diseases with an initial focus on endometriosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
FimmCyte Comparables
Compare FimmCyte with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Oriva Therapeutics | 86% | |
| EndoCyclic Therapeutics | 84% | |
| Sur180 Therapeutics | 83% |
For institutional investors. Book with your work email.
FimmCyte Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Feb 29, 2024 | ||||
| Convertible Debt | Sep 5, 2023 | ||||
| Grant | Jul 13, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
FimmCyte Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Venture Kick | Grant |
| BioInnovation Institute | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 13, 2026
Open roles increased from 0 to 2, representing 29% of headcount.
- Mar 25, 2025
Monthly visitors grew 254% MoM, reaching 1.4K.
For institutional investors. Book with your work email.
FimmCyte Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about FimmCyte's valuation, stock price, and market status.
Is FimmCyte a public or private company?
FimmCyte is a private company.
What is the current stock price of FimmCyte?
FimmCyte is a private company, so its shares have no public market price. Caplight tracks FimmCyte's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is FimmCyte worth (valuation)?
Valuation information for FimmCyte is not publicly available.
Can I buy FimmCyte stock?
FimmCyte shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was FimmCyte's last funding round?
FimmCyte's most recent funding round was Convertible Debt on February 29, 2024.
Who are the main investors in FimmCyte?
Key investors in FimmCyte include BioInnovation Institute.
Will FimmCyte IPO soon?
No public IPO plans have been announced for FimmCyte.
How can I track FimmCyte secondary market activity?
Caplight tracks bids, offers, and trades in FimmCyte's shares on secondary markets.